SynthesisAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Protein Spatial Structure Meets Artificial Intelligence: Revolutionizing Drug Synergy-Antagonism in Precision Medicine.
Synthesis in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Protein Spatial Structure Meets Artificial Intelligence: Revolutionizing Drug Synergy-Antagonism in Precision Medicine.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Pooled it
- Traditional Chinese Medicine Formulas in Delaying Aging: From Theoretical Foundations to Molecular Mechanisms and Translational Perspectives.Journal of cellular and molecular medicine · 2026Review
- Neuropsychiatric drug development in China: Current status and emerging trends.Molecular psychiatry · 2026Review
- A novel risk model of cholesterol metabolism-related mRNAs for predicting overall survival and immune signature in glioma based on machine learning and multi-omics data.Translational cancer research · 2026Article
- Rethinking Nature's Pharmacy: AI Era and Natural Product Drug Discovery.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Research progress on antiviral drugs and vaccines for severe fever with thrombocytopenia syndrome.Frontiers in immunology · 2026Review
- Zebrafish as a translational model for peptide-mediated synaptic dysfunction related to obesity.Frontiers in synaptic neuroscience · 2026Review
- Dapansutrile in multidisciplinary therapeutic applications: mechanisms and clinical perspectives.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Targeted drug design and development, as a core area of modern pharmaceutical research, critically depends on the assessment of protein site druggability as a fundamental component. This review systematically examines the latest research progress and application prospects of drug synergy and antagonism prediction methods that integrate protein three-dimensional spatial structure with artificial intelligence (AI) technologies. This review showcases the molecular biological mechanisms of drug synergism vs antagonism mediated by transcription factors, signal pathway regulation, and membrane transport proteins, and subsequently delves into the molecular structural basis of protein-drug interactions, including precise identification methods for drug binding sites, optimization strategies for molecular docking techniques, and the mechanisms and structural characteristics of multi-target drugs. The review systematically evaluates the practical application progress of AI technologies, especially machine learning and deep learning algorithms, in predicting drug synergy-antagonism effects, as well as the methodological approaches for constructing and evaluating the performance of AI prediction models that integrate multi-source biological data. These research findings provide a solid theoretical foundation for the precision treatment of cancer, infectious diseases, and metabolic disorders, with significant clinical and translational implications for advancing personalized medicine strategies in clinical practice and facilitating the rational design and development of novel multi-target drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.